Global and United States Drug Repositioning Market Report & Forecast 2022-2028

Drug repurposing (also called drug repositioning, reprofiling or re-tasking) is a strategy for identifying new uses for approved or investigational drugs that are outside the scope of the original medical indication. This strategy offers various advantages over developing an entirely new drug for a given indication.
Market Analysis and Insights: Global and United States Drug Repositioning Market
This report focuses on global and United States Drug Repositioning market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Drug Repositioning market size is estimated to be worth US$ 27610 million in 2022 and is forecast to a readjusted size of US$ 36370 million by 2028 with a CAGR of 4.7% during the review period. Fully considering the economic change by this health crisis, by Type, Generic Drugs accounting for % of the Drug Repositioning global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Cardiovascular Diseases was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
Global Drug Repositioning key players include Teva, Novartis, Mylan, Johnson & Johnson, Pfizer, etc. Global top five manufacturers hold a share about 15%.
North America is the largest market, with a share about 40%, followed by Europe and China, both have a share over 30 percent.
In terms of product, Generic Drugs is the largest segment, with a share about 65%. And in terms of application, the largest application is Cancer, followed by Cardiovascular Diseases.
Global Drug Repositioning Scope and Market Size
Drug Repositioning market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Drug Repositioning market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Drug Repositioning market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Generic Drugs
Clinical Trial Failed Drugs
Segment by Application
Cardiovascular Diseases
Mental Illness
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Teva
Novartis
Mylan
Johnson & Johnson
Pfizer
Bausch Health
GSK
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma